Sue Leurgans to Levodopa
This is a "connection" page, showing publications Sue Leurgans has written about Levodopa.
Connection Strength
0.305
-
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
Score: 0.085
-
Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
Score: 0.067
-
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
Score: 0.052
-
Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
Score: 0.050
-
Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol. 2004 Jan-Feb; 27(1):30-2.
Score: 0.015
-
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
Score: 0.014
-
Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
Score: 0.013
-
Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
Score: 0.010